Use of Gemcitabine Plus Carboplatin Is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4–5

PURPOSE: This study aimed to investigate the clinical outcomes with gemcitabine-carboplatin (GCb), the standard treatment for patients with advanced urothelial carcinoma (UC) who are ineligible for cisplatin-based regimens, in advanced UC patients with a glomerular filtration rate (GFR) < 30 mL/m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyung-Don, Im, Hyeon-Su, Kim, Jwa Hoon, Jeong, Hyehyun, Yoon, Shin Kyo, Park, Inkeun, Lee, Jae Lyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524029/
https://www.ncbi.nlm.nih.gov/pubmed/33677847
http://dx.doi.org/10.4143/crt.2021.091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524029/
https://www.ncbi.nlm.nih.gov/pubmed/33677847
http://dx.doi.org/10.4143/crt.2021.091

Ejemplares similares